After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its protein-based COVID-19 vaccine, Nuvaxovid (COVID-19 vaccine, adjuvanted).

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, from the United States, the European Union, Japan and Taiwan.